Description of the medicine: Triftazin (Triftazinum)
TRIFTAZIN (Triftazinum). 2-Trifluoromethyl-10- [3- (1-methylpiperazinyl-4) propyl] phenothiazine dihydrochloride.
Synonyms: Stelazine, Trifluoperazin, Aquil, Calmazine, Clinazine, Equazine, Eskazine, Fluazine, Fluperin, Jatroneural, Modalina, Parstelin, Stelazine, Terfluzine, Trifluoperazini hydrochloridum, Trifluperazine, Trifluperazine Trifluorrazine, Trifluorrazine, Trifluorrazine, Trifluorrazine
White or slightly greenish-yellow crystalline powder. Easily soluble in water, soluble in alcohol. It gets dark in the light.
In terms of chemical structure, triftazine differs from chlorpromazine in that instead of the chlorine atom in position 2 of the phenothiazine nucleus it contains a CF3 group, and in the side chain it contains the piperazine nucleus substituted at the nitrogen atom in position 4 by the CH 3 group (as in meterazine).
Triftazine is one of the most active antipsychotic drugs. The antipsychotic effect is combined with a moderate stimulating (energizing) effect. In hallucinatory and hallucinatory delusional states, a sedative effect is manifested. The drug has a strong antiemetic effect.
Unlike chlorpromazine, triftazine has a weak adrenolytic effect. Potentiates the effect of sleeping pills less; does not have antihistamine, antispasmodic and anticonvulsant activity. It has a strong cataleptic effect.
They are used in psychiatric practice for the treatment of schizophrenia, especially paranoid, nuclear and sluggish, with other mental diseases occurring with delusional symptoms and hallucinations, with involutional psychoses, neuroses and other diseases of the central nervous system.
Triftazin has a more pronounced effect on productive psychotic symptoms (hallucinations, delirium) than chlorpromazine. A distinctive feature of triftazine is the lack of stiffness, general weakness, and stupor in its use; on the contrary, patients often become more lively, begin to show interest in the environment, are more easily involved in work processes. In the early days of treatment, drowsiness may occur.
Prescribe triftazine orally (after eating) and intramuscularly. A single oral dose at the beginning of treatment is usually 0.005 g (5 mg). In the future, the dose is gradually increased by 0.005 g per dose to a total daily dose of 0.03 - 0.08 g (in some cases, up to 0.1 - 0.12 g per day); the daily dose is divided into 2 to 4 doses. Upon reaching the therapeutic effect, the optimal doses are maintained for 1 to 3 months, then they are reduced to 0.02 to 0.005 g per day. These doses are subsequently prescribed as supportive.
Intramuscularly administered triftazine in cases requiring a quick effect. Initial doses are 0.001 to 0.002 g (1 to 2 mg). Injections are repeated after 4 to 6 hours. The daily dose is usually up to 0.006 g (6 mg), in rare cases, up to 0.01 g (10 mg).
In patients with alcoholism, triftazine is used to treat acute and chronic hallucinatory and delusional psychoses, and to stop psychomotor agitation. In acute psychotic conditions, treatment begins with intramuscular injection, moving on to ingestion after the removal of the acute phenomena of psychosis.